Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Tan, Eng Huat; Rolski, Janusz; Grodzki, Tomasz; Schneider, C.; Gatzemeier, U.; Zatloukal, Petr; Aitini, Enrico; Cartenì, Giacomo; Riska, Henrik; Tsai, Ying‐Huang; Abratt, Raymond P.

doi:10.1093/annonc/mdn774

Cited by 55 publications

(70 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lastly, vinorelbine as a single agent with radiation therapy was well tolerated, and the response rate was approximately 60% 8 . In combination trials in nsclc, an acceptable safety and efficacy profile was observed with vinorelbine plus platinum-based chemotherapy, as well as with oral or intravenous formulations of vinorelbine alone, compared with platinum plus taxanes [9][10][11][12] .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The cisplatin/vinorelbine doublet is a well studied and active doublet in the treatment of NSCLC either in the adjuvant [27,28] or in the advanced disease setting [29][30][31]. On the other hand, this combination is very toxic with severe neutropenia occurring in more than 40%-80% of the patients [27,29,31].…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, this combination is very toxic with severe neutropenia occurring in more than 40%-80% of the patients [27,29,31]. Thus, we considered of interest a study evaluating the combination of metronomic administration of vinorelbine with cisplatin, a strategy which is likely to have a more favorable toxicity profile.…”

Section: Discussionmentioning

confidence: 99%

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

Pallis

Chandrinos

Pavlakou

et al. 2010

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…No significant difference by histology was observed in the efficacy of these regimens; however, overall, a survival advantage was observed for patients with scc compared with those with adenocarcinoma (p = 0.0021). In the phase iii Global Lung Oncology Branch trial 3, patients with advanced nsclc were treated with first-line vinorelbine-cisplatin or with docetaxel-cisplatin 61 . In patients with scc, median os was 9.8 months in the docetaxel arm and 8.9 months in the vinorelbine arm; the respective orrs were 28% and 25%.…”

Section: Taxanes and Histologymentioning

confidence: 99%

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

View full text Add to dashboard Cite

standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .Recently, nab-paclitaxel, a 130-nm albuminbound ("nab") form of paclitaxel designed to use endogenous albumin pathways to increase intratumoural concentrations of the active drug, demonstrated improved antitumour activity and tolerability compared with sb-paclitaxel when both were used in combination with carboplatin in the first-line treatment of patients with advanced nsclc 12 . Based on the results of a phase iii trial, nab-paclitaxel in combination with carboplatin was approved in 2012 as first-line therapy for the treatment of locally advanced or metastatic nsclc in patients who are not candidates for curative surgery or radiation therapy 12,13 . The present review summarizes the clinical experience to date with taxanes in the first-line treatment of nsclc. DISCUSSION Taxane-Platinum CombinationsIn landmark nsclc studies, overall response rates (orrs) were higher with taxane-platinum combinations than with other chemotherapy regimens ( Table i). Historically, sb-paclitaxel given in combination with carboplatin or cisplatin demonstrated a median overall survival (os) of 7.7-10 months and an orr of 17%-41% [7][8][9]11,14,[16][17][18]22 . ABSTRACTBased on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxelcarboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

show abstract

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Cited by 55 publications

References 31 publications

Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status

Efficacy of Metronomic Vinorelbine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer and Poor Performance Status

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About